Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07378527 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

StatusRecruiting
PhasePhase 2/3
Started
View on ClinicalTrials.gov ↗

Record History

  1. Primary endpoint(s) modified Recruitment opened · Start date changed from estimate of Mar 2026 to Feb 13, 2026 · Site details revised at 30 of 30 sitesv2 Show 3 more changesShow less
    • Recruitment opened
    • Start date changed from estimate of Mar 2026 to Feb 13, 2026
    • Site details revised at 30 of 30 sites

    See this version in full on ClinicalTrials.gov ↗

  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines
Trial Details
NCT Number NCT07378527
Lead Sponsor Beijing InnoCare Pharma Tech Co., Ltd.
Conditions Chronic Spontaneous Urticaria (CSU)
Enrollment 344 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov